[Skip to Content]
[Skip to Content Landing]

Health Disparities and Triple-Negative Breast Cancer in African American WomenA Review

Educational Objective
To describe oncologic anthropology and racial/ethnic variation in cancer using breast cancer as a model.
1 Credit CME
Abstract

Importance  Variation in cancer incidence and outcome has well-documented correlations with racial/ethnic identity. In the United States, the possible genetic and ancestral hereditary explanations for these associations are confounded by socioeconomic, cultural, and lifestyle patterns. Differences in the breast cancer burden of African American compared with European/white American women represent one of the most notable examples of disparities in oncology related to racial/ethnic identity. Elucidating the source of these associations is imperative in achieving the promise of the national Precision Medicine Initiative.

Observations  Population-based breast cancer mortality rates have been higher for African American compared with white American women since the early 1980s, largely reflecting declines in mortality that have been disproportionately experienced among white American patients and at least partly explained by the advent of endocrine therapy that is less effective in African American women because of the higher prevalence of estrogen receptor–negative disease. The increased risk of triple-negative breast cancer in African American women as well as western, sub-Saharan African women compared with white American, European, and east African women furthermore suggests that selected genetic components of geographically defined African ancestry are associated with hereditary susceptibility for specific patterns of mammary carcinogenesis. Disentangling health care access barriers, as well as reproductive, lifestyle, and dietary factors from genetic contributions to breast cancer disparities remains challenging. Epigenetics and experiences of societal inequality (allostatic load) increase the complexity of studying breast cancer risk related to racial/ethnic identity.

Conclusions and Relevance  Oncologic anthropology represents a transdisciplinary field of research that can combine the expertise of population geneticists, multispecialty oncologists, molecular epidemiologists, and behavioral scientists to eliminate breast cancer disparities related to racial/ethnic identity and advance knowledge related to the pathogenesis of triple-negative breast cancer.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Lisa A. Newman, MD, MPH, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202 (newman1@hfhs.org).

Accepted for Publication: November 17, 2016.

Published Online: March 29, 2017. doi:10.1001/jamasurg.2017.0005

Author Contributions: Drs Newman and Kaljee had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Newman.

Acquisition, analysis, or interpretation of data: Both authors.

Drafting of the manuscript: Both authors.

Critical revision of the manuscript for important intellectual content: Both authors.

Statistical analysis: Newman.

Obtained funding: Newman.

Administrative, technical, or material support: Both authors.

Study supervision: Newman.

Conflict of Interest Disclosures: None reported.

Funding/Support: Funding was provided from Susan G. Komen for the Cure through Komen Scholars Leadership Grant HFHS F11047.

Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Jack Butler (Department of Surgery, Henry Ford Hospital) assisted with adapting and creating Figure 1 depicting the African Diaspora. There was no financial compensation other than salary.

References
1.
Freeman  HP.  Commentary on the meaning of race in science and society.  Cancer Epidemiol Biomarkers Prev. 2003;12(3):232s-236s.PubMedGoogle Scholar
2.
Brawley  OW.  Health disparities in breast cancer.  Obstet Gynecol Clin North Am. 2013;40(3):513-523.PubMedGoogle ScholarCrossref
3.
Williams  DR, Mohammed  SA, Shields  AE.  Understanding and effectively addressing breast cancer in African American women: unpacking the social context.  Cancer. 2016;122(14):2138-2149.PubMedGoogle ScholarCrossref
4.
Jiagge  E, Jibril  AS, Chitale  D,  et al.  Comparative analysis of breast cancer phenotypes in African American, white American, and west versus east African patients: correlation between African ancestry and triple-negative breast cancer.  Ann Surg Oncol. 2016;23(12):3843-3849.PubMedGoogle ScholarCrossref
5.
Newman  LA.  Disparities in breast cancer and African ancestry: a global perspective.  Breast J. 2015;21(2):133-139.PubMedGoogle ScholarCrossref
6.
DeSantis  CE, Fedewa  SA, Goding Sauer  A, Kramer  JL, Smith  RA, Jemal  A.  Breast cancer statistics, 2015: convergence of incidence rates between black and white women.  CA Cancer J Clin. 2016;66(1):31-42.PubMedGoogle ScholarCrossref
7.
DeSantis  CE, Siegel  RL, Sauer  AG,  et al.  Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.  CA Cancer J Clin. 2016;66(4):290-308.PubMedGoogle ScholarCrossref
8.
US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 incidence and mortality web-based report. Atlanta: US Dept of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. http://www.cdc.gov/uscs. Published 2016. Accessed September 6, 2016.
9.
Kohler  BA, Sherman  RL, Howlader  N,  et al.  Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state.  J Natl Cancer Inst. 2015;107(6):djv048.PubMedGoogle ScholarCrossref
10.
Anderson  WF, Chatterjee  N, Ershler  WB, Brawley  OW.  Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.  Breast Cancer Res Treat. 2002;76(1):27-36.PubMedGoogle ScholarCrossref
11.
Newman  LA.  Parsing the etiology of breast cancer disparities.  J Clin Oncol. 2016;34(9):1013-1014.PubMedGoogle ScholarCrossref
12.
Newman  LA, Reis-Filho  JS, Morrow  M, Carey  LA, King  TA.  The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.  Ann Surg Oncol. 2015;22(3):874-882.PubMedGoogle ScholarCrossref
13.
Carey  LA, Perou  CM, Livasy  CA,  et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.  JAMA. 2006;295(21):2492-2502.PubMedGoogle ScholarCrossref
14.
Amirikia  KC, Mills  P, Bush  J, Newman  LA.  Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations.  Cancer. 2011;117(12):2747-2753.PubMedGoogle ScholarCrossref
15.
Akinyemiju  T, Moore  JX, Altekruse  SF.  Breast cancer survival in African-American women by hormone receptor subtypes.  Breast Cancer Res Treat. 2015;153(1):211-218.PubMedGoogle ScholarCrossref
16.
Martin  N, Wingfield  J.  USPSTF screening recommendations for breast cancer: the potential impact on the African American community.  J Health Care Poor Underserved. 2012;23(2)(suppl):91-97.PubMedGoogle ScholarCrossref
17.
Macartney  S., Bishaw  A, Fontenot  K. Poverty rates for selected detailed race and Hispanic groups by state and place: 2007-2011; American Community Survey Briefs. American Community Series Brief/11-17. US Department of Commerce, Economics and Statistics Administration. US Census Bureau. http://www.census.gov/prod/2013pubs/acsbr11-17.pdf. Published February 2013. Accessed March 3, 2017
18.
Ward  BW, Clarke  TC, Freeman  GJ, Schiller  JS. Early release of selected estimates based on data from the 2014 National Health Interview Survey. https://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201506.pdf. Released June 2015. Accessed March 3, 2017.
19.
Ward  E, Jemal  A, Cokkinides  V,  et al.  Cancer disparities by race/ethnicity and socioeconomic status.  CA Cancer J Clin. 2004;54(2):78-93.PubMedGoogle ScholarCrossref
20.
Shavers  VL, Brown  ML.  Racial and ethnic disparities in the receipt of cancer treatment.  J Natl Cancer Inst. 2002;94(5):334-357.PubMedGoogle ScholarCrossref
21.
Tammemagi  CM, Nerenz  D, Neslund-Dudas  C, Feldkamp  C, Nathanson  D.  Comorbidity and survival disparities among black and white patients with breast cancer.  JAMA. 2005;294(14):1765-1772.PubMedGoogle ScholarCrossref
22.
Hershman  D, Weinberg  M, Rosner  Z,  et al.  Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.  J Natl Cancer Inst. 2003;95(20):1545-1548.PubMedGoogle ScholarCrossref
23.
Newman  LA, Griffith  KA, Jatoi  I, Simon  MS, Crowe  JP, Colditz  GA.  Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.  J Clin Oncol. 2006;24(9):1342-1349.PubMedGoogle ScholarCrossref
24.
Albain  KS, Unger  JM, Crowley  JJ, Coltman  CA  Jr, Hershman  DL.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.  J Natl Cancer Inst. 2009;101(14):984-992.PubMedGoogle ScholarCrossref
25.
Andaya  AA, Enewold  L, Horner  MJ, Jatoi  I, Shriver  CD, Zhu  K.  Socioeconomic disparities and breast cancer hormone receptor status.  Cancer Causes Control. 2012;23(6):951-958.PubMedGoogle ScholarCrossref
26.
Akinyemiju  TF, Pisu  M, Waterbor  JW, Altekruse  SF.  Socioeconomic status and incidence of breast cancer by hormone receptor subtype.  Springerplus. 2015;4:508.PubMedGoogle ScholarCrossref
27.
Millikan  RC, Newman  B, Tse  CK,  et al.  Epidemiology of basal-like breast cancer.  Breast Cancer Res Treat. 2008;109(1):123-139.PubMedGoogle ScholarCrossref
28.
Chlebowski  RT, Chen  Z, Anderson  GL,  et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome.  J Natl Cancer Inst. 2005;97(6):439-448.PubMedGoogle ScholarCrossref
29.
Newman  LA, Stark  A, Chitale  D,  et al.  Association between benign breast disease in African American women and white American women and subsequent triple-negative breast cancer  [published online December 22, 2016].  JAMA Oncol. doi:10.1001/jamaoncol.2016.5598Google Scholar
30.
Ambrosone  CB, Young  AC, Sucheston  LE,  et al.  Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry.  Oncotarget. 2014;5(1):237-248.PubMedGoogle Scholar
31.
Mersha  TB, Abebe  T.  Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities.  Hum Genomics. 2015;9:1.PubMedGoogle ScholarCrossref
32.
Ferla  R, Calò  V, Cascio  S,  et al.  Founder mutations in BRCA1 and BRCA2 genes.  Ann Oncol. 2007;18(suppl 6)(suppl 6):vi93-vi98.PubMedGoogle Scholar
33.
Karami  F, Mehdipour  P.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.  Biomed Res Int. 2013;2013:928562.PubMedGoogle ScholarCrossref
34.
Akbari  MR, Donenberg  T, Lunn  J,  et al.  The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas.  Clin Genet. 2014;85(1):64-67.PubMedGoogle ScholarCrossref
35.
Fackenthal  JD, Zhang  J, Zhang  B,  et al.  High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.  Int J Cancer. 2012;131(5):1114-1123.PubMedGoogle ScholarCrossref
36.
Francies  FZ, Wainstein  T, De Leeneer  K,  et al.  BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.  BMC Cancer. 2015;15:912.PubMedGoogle ScholarCrossref
37.
Palmer  JR, Ruiz-Narvaez  EA, Rotimi  CN,  et al.  Genetic susceptibility loci for subtypes of breast cancer in an African American population.  Cancer Epidemiol Biomarkers Prev. 2013;22(1):127-134.PubMedGoogle ScholarCrossref
38.
Palmer  JR, Ambrosone  CB, Olshan  AF.  A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.  Cancer Causes Control. 2014;25(3):309-319.PubMedGoogle ScholarCrossref
39.
Haddad  SA, Ruiz-Narváez  EA, Haiman  CA,  et al.  An exome-wide analysis of low frequency and rare variants in relation to risk of breast cancer in African American Women: the AMBER Consortium.  Carcinogenesis. 2016;37(9):870-877.PubMedGoogle ScholarCrossref
40.
Huo  D, Feng  Y, Haddad  S,  et al.  Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer.  Hum Mol Genet. 2016;25(21):4835-4846.PubMedGoogle Scholar
41.
National Cancer Institute. NCI launches largest-ever study of breast cancer genetics in black women. http://www.cancer.gov/news-events/press-releases/2016/breast-cancer-genetics-black-women. Published July 6, 2016. Accessed September 12, 2016.
42.
Brewster  AM, Chavez-MacGregor  M, Brown  P.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.  Lancet Oncol. 2014;15(13):e625-e634.PubMedGoogle ScholarCrossref
43.
Kantelhardt  EJ, Mathewos  A, Aynalem  A,  et al.  The prevalence of estrogen receptor-negative breast cancer in Ethiopia.  BMC Cancer. 2014;14:895.PubMedGoogle ScholarCrossref
44.
Jemal  A, Fedewa  SA.  Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women?  Breast Cancer Res Treat. 2012;135(3):867-873.PubMedGoogle ScholarCrossref
45.
Campbell  MC, Hirbo  JB, Townsend  JP, Tishkoff  SA.  The peopling of the African continent and the diaspora into the new world.  Curr Opin Genet Dev. 2014;29:120-132.PubMedGoogle ScholarCrossref
46.
Salas  A, Carracedo  A, Richards  M, Macaulay  V.  Charting the ancestry of African Americans.  Am J Hum Genet. 2005;77(4):676-680.PubMedGoogle ScholarCrossref
47.
Agboola  AO, Banjo  AA, Anunobi  CC,  et al.  Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.  Malays J Pathol. 2014;36(1):3-17.PubMedGoogle Scholar
48.
Adjei  EK, Owusu-Afriyie  O, Awuah  B, Stalsberg  H.  Hormone receptors and Her2 expression in breast cancer in sub-Saharan Africa: a comparative study of biopsies from Ghana and Norway.  Breast J. 2014;20(3):308-311.PubMedGoogle ScholarCrossref
49.
Luyeye Mvila  G, Batalansi  D, Praet  M,  et al.  Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.  Breast. 2015;24(5):642-648.PubMedGoogle ScholarCrossref
50.
Dickens  C, Duarte  R, Zietsman  A,  et al.  Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.  Cancer Epidemiol Biomarkers Prev. 2014;23(11):2311-2321.PubMedGoogle ScholarCrossref
51.
McCormack  VA, Joffe  M, van den Berg  E,  et al.  Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.  Breast Cancer Res. 2013;15(5):R84.PubMedGoogle ScholarCrossref
52.
Amadori  D, Serra  P, Bravaccini  S,  et al.  Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations.  Breast Cancer Res Treat. 2014;145(1):177-183.PubMedGoogle ScholarCrossref
53.
Trinkaus  ME, Sayed  S, Gakinya  SM, Moloo  Z, Hanna  W, Rahim  Y.  Triple negative and basal-like breast cancer in East Africa.  Breast J. 2011;17(4):438-440.PubMedGoogle ScholarCrossref
54.
Bird  PA, Hill  AG, Houssami  N.  Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?  Ann Surg Oncol. 2008;15(7):1983-1988.PubMedGoogle ScholarCrossref
55.
Nyagol  J, Nyong’o  A, Byakika  B,  et al.  Routine assessment of hormonal receptor and HER-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.  Anal Quant Cytol Histol. 2006;28(2):97-103.PubMedGoogle Scholar
56.
Nalwoga  H, Arnes  JB, Wabinga  H, Akslen  LA.  Frequency of the basal-like phenotype in African breast cancer.  APMIS. 2007;115(12):1391-1399.PubMedGoogle ScholarCrossref
57.
Roy  I, Othieno  E.  Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases.  Arch Pathol Lab Med. 2011;135(2):194-199.PubMedGoogle Scholar
58.
Mbonde  MP, Amir  H, Schwartz-Albiez  R, Akslen  LA, Kitinya  JN.  Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania.  Oncol Rep. 2000;7(2):277-283.PubMedGoogle Scholar
59.
Burson  AM, Soliman  AS, Ngoma  TA,  et al.  Clinical and epidemiologic profile of breast cancer in Tanzania.  Breast Dis. 2010;31(1):33-41.PubMedGoogle ScholarCrossref
60.
Sayed  S, Moloo  Z, Wasike  R,  et al.  Is breast cancer from Sub Saharan Africa truly receptor poor? prevalence of ER/PR/HER2 in breast cancer from Kenya.  Breast. 2014;23(5):591-596.PubMedGoogle ScholarCrossref
61.
Galukande  M, Wabinga  H, Mirembe  F, Karamagi  C, Asea  A.  Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population.  Pan Afr Med J. 2014;17:249.PubMedGoogle Scholar
62.
Rambau  P, Masalu  N, Jackson  K, Chalya  P, Serra  P, Bravaccini  S.  Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients.  BMC Res Notes. 2014;7(1):399.PubMedGoogle ScholarCrossref
63.
Fourati  A, Boussen  H, El May  MV,  et al.  Descriptive analysis of molecular subtypes in Tunisian breast cancer.  Asia Pac J Clin Oncol. 2014;10(2):e69-e74.PubMedGoogle ScholarCrossref
64.
Rais  G, Raissouni  S, Aitelhaj  M,  et al.  Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.  BMC Womens Health. 2012;12:35.PubMedGoogle ScholarCrossref
65.
Bennis  S, Abbass  F, Akasbi  Y,  et al.  Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study.  BMC Res Notes. 2012;5:436.PubMedGoogle ScholarCrossref
66.
El-Hawary  AK, Abbas  AS, Elsayed  AA, Zalata  KR.  Molecular subtypes of breast carcinoma in Egyptian women: clinicopathological features.  Pathol Res Pract. 2012;208(7):382-386.PubMedGoogle ScholarCrossref
67.
Salhia  B, Tapia  C, Ishak  EA,  et al.  Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology.  BMC Womens Health. 2011;11:44.PubMedGoogle ScholarCrossref
68.
Cherbal  F, Gaceb  H, Mehemmai  C,  et al.  Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.  Breast Dis. 2015;35(2):95-102.PubMedGoogle ScholarCrossref
69.
Aiad  HA, Wahed  MM, Asaad  NY, El-Tahmody  M, Elhosary  E.  Immunohistochemical expression of GPR30 in breast carcinoma of Egyptian patients: an association with immunohistochemical subtypes.  APMIS. 2014;122(10):976-984.PubMedGoogle ScholarCrossref
70.
Huo  D, Ikpatt  F, Khramtsov  A,  et al.  Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.  J Clin Oncol. 2009;27(27):4515-4521.PubMedGoogle ScholarCrossref
71.
Ly  M, Antoine  M, Dembélé  AK,  et al.  High incidence of triple-negative tumors in sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital.  Oncology. 2012;83(5):257-263.PubMedGoogle ScholarCrossref
72.
Der  EM, Gyasi  RK, Tettey  Y,  et al.  Triple-negative breast cancer in Ghanaian women: the Korle Bu teaching hospital experience.  Breast J. 2015;21(6):627-633.PubMedGoogle ScholarCrossref
73.
Ohene-Yeboah  M, Adjei  E.  Breast cancer in Kumasi, Ghana.  Ghana Med J. 2012;46(1):8-13.PubMedGoogle Scholar
74.
Nwafor  CC, Keshinro  SO.  Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: private practice experience.  Niger J Clin Pract. 2015;18(4):553-558.PubMedGoogle ScholarCrossref
75.
Proctor  E, Kidwell  KM, Jiagge  E,  et al.  Characterizing breast cancer in a population with increased prevalence of triple-negative breast cancer: androgen receptor and ALDH1 expression in Ghanaian women.  Ann Surg Oncol. 2015;22(12):3831-3835.PubMedGoogle ScholarCrossref
76.
Lehmann  BD, Bauer  JA, Chen  X,  et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.  J Clin Invest. 2011;121(7):2750-2767.PubMedGoogle ScholarCrossref
77.
Burstein  MD, Tsimelzon  A, Poage  GM,  et al.  Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.  Clin Cancer Res. 2015;21(7):1688-1698.PubMedGoogle ScholarCrossref
78.
Keenan  T, Moy  B, Mroz  EA,  et al.  Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence.  J Clin Oncol. 2015;33(31):3621-3627.PubMedGoogle ScholarCrossref
79.
Lindner  R, Sullivan  C, Offor  O,  et al.  Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.  PLoS One. 2013;8(11):e71915.PubMedGoogle ScholarCrossref
80.
Jiagge  E, Oppong  J, Bensenhaver  J,  et al.  Breast Cancer and African Ancestry: lessons learned at the 10-year anniversary of the Ghana-Michigan research partnership and international registry.  J Glob Oncol. 2016;2(5):302-310.Google ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements